Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007

Erasca announced a clinical trial collaboration and supply agreement, CTCSA, with Pierre Fabre for the BRAF inhibitor encorafenib within key international territories. This agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer. This combination is being investigated as part of the ongoing Phase 1b/2 HERKULES-3 master protocol in patients with gastrointestinal malignancies. Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific. "We are excited to work with Pierre Fabre, a leader in precision oncology, on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets. Resistance mechanisms, particularly through MAPK reactivation, limit long-term benefit with current standard of care BRAF-targeted treatments. By blocking RAS/MAPK pathway signaling at the most distal node, ERK1/2, ERAS-007 can potentially prevent pathway reactivation."